Home/Stocks/TM
Public stock intelligence

Toyota Motor Corporation with price, financials, news flow, and insider context in one page.

Toyota Motor Corporation is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where TM sits inside Consumer Cyclical and Auto Manufacturers, and the key financial markers that matter before moving into a fuller research workflow.

Consumer CyclicalAuto ManufacturersNYQJapan
Live price
$187.09
Session move
+2.99% today
Next earnings
Aug 6, 2026
Market cap
221.54B
Volume
349.68K
52-week range
24% through the 52-week range
Forward P/E
11.86
Revenue growth
1.9%
Dividend yield
100.0%
Price history
Daily closes for TM, with a quick range selector for public research.
About the company

Toyota Motor Corporation designs, manufactures, assembles, and sells passenger vehicles, minivans and commercial vehicles, and related parts and accessories in Japan, North America, Europe, Asia, Central and South America, Oceania, Africa, the Middle East, and internationally. It operates through Automotive, Financial Services, and All Other segments. The company offers subcompact and compact cars; mini-vehicles; mid-size, luxury, sports, and specialty cars; recreational and sport-utility vehicles; pickup trucks; minivans; trucks; and buses. It also develops and sells battery electric vehicles and batteries. In addition, the company provides financial services, such as retail financing and leasing, wholesale financing, insurance, and credit cards. Further, it operates GAZOO.com, a web portal for automobile information, as well as engages in telecommunications and other businesses. It offers vehicles under the Toyota and Lexus brand names. Toyota Motor Corporation was founded in 1933 and is headquartered in Toyota, Japan.

Employees
390,927
Beta
0.33
ROE
10.2%
Current ratio
1.27
Visit company website
Research framing

This page is structured for research context, not a trade call. It gives you a clean read on where TM sits in its range, what the last few quarters look like, and which headlines are shaping attention.

For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.

Quarterly financials
QuarterRevenueNet incomeFree cash flow
Q4 202513.46T1.26T-488.9B
Q3 202512.38T932.08B-204.08B
Q2 202512.25T841.35B633.56B
Q1 202512.36T664.7B94.53B
Insider activity

Recent insider transaction detail is not available for this symbol right now.

Recent news
ForexForexLive53m ago
BOC Meeting Minutes: Sees future rate adjustments would likely be small.

The BOC Meeting meeting minutes are out for the April 29 meeting. International economyMiddle East war increased uncertainty, pushed oil prices sharply higher, and added to global inflation pressur...

MacroGoogle News1h ago
Read the internal memo from LinkedIn's CEO on layoffs and 'scaling back investments' - Business Insider

Read the internal memo from LinkedIn's CEO on layoffs and 'scaling back investments'  Business InsiderExclusive: LinkedIn planning to lay off 5% of staff in latest tech-sector cuts, sourc...

SectorGoogle News1h ago
Google on its ‘continued commitment to Chromebooks’ after Googlebooks - 9to5Google

Google on its ‘continued commitment to Chromebooks’ after Googlebooks  9to5GoogleIntroducing Googlebook, designed for Gemini Intelligence  blog.googleGooglebooks Could Be the Ul...

MacroGoogle News2h ago
Social Security recipients could get a nearly 4% cost-of-living adjustment, forecasters say - CBS News

Social Security recipients could get a nearly 4% cost-of-living adjustment, forecasters say  CBS NewsSocial Security now poised for big ‘Trump Bump’ in the months ahead — here’s how much ...

SectorCNBC2h ago
Alibaba jumps as it strikes bullish tone on AI investments, even as profit plunges

Alibaba on Wednesday said its core profitability plunged in the March quarter amid heavy investments in tech and e-commerce.

CryptoCNBC2h ago
This pharma name targeting aging has soared this year. BTIG thinks it can double from here

The investment firm initiated coverage of the biopharmaceutical name with a buy rating.

Why this page ranks

A public stock page should answer the first research questions before asking for a signup.

This TM page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.

The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.